Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice-Reference-Cited by-同舟云学术

Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice

Published:2017-03 Issue:1 Volume:28 Page:17-27
ISSN:2324-8637
Container-title:Human Gene Therapy Clinical Development
language:en
Short-container-title:Human Gene Therapy Clinical Development

Author:

Carriglio Nicola¹²,Klapwijk Jan³,Hernandez Raisa Jofra¹²,Vezzoli Michela²,Chanut Franck³,Lowe Rhiannon³,Draghici Elena¹²,Nord Melanie⁴,Albertini Paola²,Cristofori Patrizia²³,Richards Jane³,Staton Hazel⁵,Appleby Jonathan³,Aiuti Alessandro¹⁶,Sauer Aisha V.¹²

Affiliation:

1. Pathogenesis and Therapy of Primary Immunodeficiencies Unit, San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific Institute, Milan, Italy

2. GLP SR-TIGET Test Facility, Ospedale San Rafaele, Milan, Italy

3. GlaxoSmithKline, In Vitro In Vivo Translation, Ware, United Kingdom

4. GlaxoSmithKline, Regulatory Affairs, King of Prussia, Pennsylvania

5. Covance Laboratories Ltd, Harrogate, United Kingdom

6. Vita-Salute San Raffaele University, Milan, Italy

Publisher

Mary Ann Liebert Inc

Subject

Genetics (clinical)

Link

http://www.liebertpub.com/doi/pdf/10.1089/humc.2016.191

Reference38 articles.